Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083 - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-term HIV Viral Suppression Achieved with Co-formulated Tenofovir Disoproxil Fumarate, Lamivudine, and Dolutegravir in a Patient with Transmitted Resistance to Dolutegravir and Lamivudine: Insights from HPTN 083 Case Study

  • By

  • Hannah P Moore

  • Jessica M Fogel

  • Mark A Marzinke

  • Elias K Halvas

  • Urvi M Parikh

  • John W Mellors

  • Kerri J Penrose

  • Michael Seisa

  • Christos Petropoulos

  • Amelia L Price

  • Amber Moser

  • Zhe Wang

  • Marybeth McCauley

  • Javier Valencia-Huamaní

  • Alex R Rinehart

  • James F Rooney

  • Lydia Soto-Torres

  • Beatriz Grinsztejn

  • Raphael J Landovitz

  • Susan H Eshleman

  • October 15, 2025

Share

Objective:

To report on a case of a participant with transmitted INSTI resistance and their response to ART with TDF, 3TC, and DTG, highlighting the implications for treatment strategies.

Key Findings:
  • Viral suppression was achieved within a year and sustained for over 3 years, demonstrating the effectiveness of the treatment.
  • The transmitted virus had resistance mutations but was susceptible to DTG at higher concentrations, indicating potential treatment pathways.
  • Pharmacologic testing showed DTG concentrations sufficient to overcome major resistance mutations, highlighting the importance of drug levels in treatment success.
Interpretation:

The case illustrates that effective viral suppression can be achieved in patients with transmitted INSTI resistance using TLD ART, suggesting a need for tailored treatment approaches.

Limitations:
  • Limited information on the generalizability of findings due to the single case report, indicating a need for further research.
  • Retrospective nature of resistance testing may not reflect real-time treatment decisions, emphasizing the importance of timely testing.
Conclusion:

This case supports the potential for effective ART in patients with transmitted INSTI resistance, emphasizing the importance of pharmacologic factors and personalized treatment strategies.

Original Source(s)

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083

  • by Hannah P Moore, Jessica M Fogel, Mark A Marzinke, Elias K Halvas, Urvi M Parikh, John W Mellors, Kerri J Penrose, Michael Seisa, Christos Petropoulos, Amelia L Price, Amber Moser, Zhe Wang, Marybeth McCauley, Javier Valencia-Huamaní, Alex R Rinehart, James F Rooney, Lydia Soto-Torres, Beatriz Grinsztejn, Raphael J Landovitz, Susan H Eshleman

  • October 15, 2025

Related Content

Rapid AST Speeds Care, Not Outcomes

Faster antibiotic optimization may still support use of rapid testing, particularly when paired with stewardship.

Short Antibiotics Match Outcomes in Pneumonia

Only about one in ten hospitalized patients qualified for shorter therapy in a large US analysis

Catheter stop orders may be losing ground

A 20-year national survey reveals substantial gains in infection surveillance but inconsistent use of strategies to limit unnecessary urinary catheterization.